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BALLOON CATHETER DILATION FOR CHRONIC RHINOSINUSITIS DOES NOT 
INCREASE THE FREQUENCY OF SINUS SURGERIES IN THE UNITED STATES  
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Acclarent, Menlo Park, CA, USA  
OBJECTIVES: Balloon catheter dilation (BCD) of sinus ostia performed by 
surgeons to treat patients suffering from chronic rhinosinusitis (CRS) refractory 
to medical management has recently been shown to be safe and effective as an 
in-office procedure. This approach thus provides physicians with the 
opportunity to treat patients in a low-acuity care setting, whereas traditional 
endoscopic surgery is performed in the operating room. Recent publications have 
raised concerns about the potential for this technology to increase the number of 
patients surgically treated through supplier-induced or normal, patient-driven 
demand. This study was therefore conducted to evaluate the total volume of 
sinus surgeries (including BCD procedures) from 2006 to 2011, to determine 
whether the introduction of BCD in 2005 increased sinus surgery volumes in the 
United States. METHODS: The Marketscan databases were queried from 2006 to 
2011 using CPT codes associated with functional endoscopic sinus surgery (FESS: 
CPT 31254 - 31288) and BCD (CPT 31295 - 31297). Total surgery and procedures 
counts were analyzed separately, as each surgery could include one or multiple 
FESS or BCD procedures (ie, one or multiple sinuses treated per patient). A 
projection methodology developed by Marketscan was applied to estimate US-
wide frequencies. Procedural case-mix and total average payment per surgical 
event were also analyzed for each year of interest. RESULTS: Total individual 
procedural volume growth reached an average compounded annual growth rate 
(CAGR) of 1.4% from 2006 to 2011. The number of surgeries, however, only grew 
by a CAGR of 0.9% during that timeframe, a rate comparable to that of the overall 
US population (0.8%). CONCLUSIONS: BCD did not result in significant growth of 
procedures or surgeries, thus suggesting that the criteria for selecting patients 
for surgery did not change with the introduction of BCD. The growth in 
procedures slightly outpaced that of surgeries, suggesting a potentially larger 
number of procedures per surgery.  
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OBJECTIVES: Tobacco smoking is one of the principal risk factors for cancer, 
respiratory disease, and cardiovascular disease. According to research reported 
by the WHO, the prevalence of current smokers in Russia in 2009 was 39%, and 
one-third of those who smoked in the past 12-month had made an attempt to 
quit. This study is aimed to assess co-morbidity, quality of life (QOL), work 
productivity loss, and resource utilization in Russian urban adults attempting to 
quit smoking. METHODS: Patients’ self-reported data were collected from 2011 
National Health and Wellness Survey (NHWS). Survey represented major urban 
areas in Russia. QOL was measured by the physical component score (PCS) and 
mental component score (MCS) of the Short Form-12 (SF-12). Loss of work 
productivity was measured by the Work Productivity and Activity Impairment 
instrument. Resource utilization was measured by health care provider, 
ambulance request and hospitalization in the past 6 months. RESULTS: Of the 
10,039 adult respondents, 6,092 (60.6%) had ever smoked cigarettes (38.2% 
current smokers, 43.5% former smokers, 16.2% smokers trying to quit smoking 
and 2.1% no smokers- in process to quit). Average age of attempters was 39.5 
years. Attempters group reported more co-morbidities (headache 60%, sleep 
difficulties 44%, insomnia 37%, heartburn 36%, pain 32%, depression 29%), lower 
mean scores of MCS (41.7 vs. 44.7), more number of visits to health care 
providers (4.9 vs. 4.2), and a higher absenteeism (5.5% vs. 3.8%) over the past 6 
months (absenteeism for last week) compared to those who never smoked. 
Furthermore, individuals attempting to quit group reported 26.6% work 
productivity loss compared to 22.3% in those who never smoked. All mentioned 
differences were statistically significant (p<0.05). CONCLUSIONS: In Russia, 
attempters to quit smoking suffer from impairment in mental QOL, work 
productivity loss and more co-morbidities. Findings indicate there is still an 
unmet need in individuals attempting to quit.  
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OBJECTIVES: Tuberculosis (TB) is a serious infectious disease which affects the 
respiratory system. In 2011, 10,521 new TB cases were reported in the U.S. The 
anti-TB drug class contains both first- and second-line treatments, with the first-
line regimen considered the skeleton of TB eradication. The purpose of the 
current study was to describe the trends in utilization of and spending on anti-
TB drugs generally and individual anti-TB medications in the U.S. Medicaid 
Program. METHODS: A retrospective, descriptive analysis was conducted to 
examine the trends in utilization of and spending on anti-TB medications, using 
the national Medicaid pharmacy files from 1991 quarter 1 through 2011 quarter 
2. Study drugs included isoniazid, rifampin, pyrazinamide, and ethambutol (first-
line therapies); and cycloserine, kanamycin, streptomycin, amikacin, 
capreomycin, moxifloxacin, rifater, rifamate, thioamides, paser, rifapentine and 
rifabutin (second-line therapies). Quarterly prescription numbers and 
reimbursement amounts were calculated over time by summing data for 
individual drug products. The quarterly per-prescription reimbursement as a 
proxy for drug price was computed for each drug. RESULTS: Total Medicaid 
utilization of anti-TB drugs rose by 43% from 151,344 in 1991 to 216,271 in 2011. 
Utilization of the first-line drugs increased from 47,348 in 1991 to 65,482 in 1993, 
stayed at this level for 4 years, and then decreased to an average of 43,245 per 
year. Medicaid reimbursement for anti-TB medications increased 246% ($6.5 
million to $22.4 million) between 1991 and 2011. Prices for second-line drugs 
were higher than those for traditional drugs due to absence of generic 
availability for the newer drugs. In 2011, reimbursement for second-line agents 
was 10 times that for first-line therapies. CONCLUSIONS: Utilization of anti-TB 
drugs was closely related to disease incidence. The rise in spending on second-
line agents may be due to increased usage for other indications along with rising 
prices. An effective management program for anti-TB drug prescribing might be 
helpful for Medicaid.  
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EUROPEAN EX-FACTORY PRICE DEVELOPMENT FOR GLOBAL 
PHARMACEUTICAL COMPANIES IN THE CONTEXT OF THE INTERNATIONAL 
PRICE REFERENCE (IPR) FRAMEWORK. IMPACT OF THE GERMAN HEALTH CARE 
REFORM (AMNOG) ON THE EUROPEAN PRICE DEVELOPMENT FOR INNOVATIVE 
PHARMACEUTICALS  
Ernst F 
Santen GmbH, Munich, Germany  
OBJECTIVES: To evaluate pharmaceutical pricing in the EU with a focus of cost-
containment due to International Price Reference (IPR) in the context of the 
German AMNOG on pricing in Europe. METHODS: Qualitative research identified 
guidelines for international price reference from each national reimbursement 
body (focusing on 10 major EU countries). Reimbursement submissions and 
results of price negotiations per country were also reviewed to gain insight into 
the application of pricing guidelines. Findings are based on review of the 
guidelines, selected appraisals and interviews with national payers in Germany, 
France and UK. RESULTS: In consideration of existing European price 
differences, high-price countries have so far increasingly attempted to also lower 
their pharmaceutical prices: preferably with different cost containment policies 
and measurements and in addition referencing low-price countries in 
international price reference (IPR). In both situations, an international downward 
effect on pricing threatens to happen for global pharmaceutical companies 
investing in Europe. This creates a European pricing and reimbursement network 
of connections of countries referencing each other with the tendency to develop 
a standard price across European countries. Germany is directly price referenced 
by more than 15 countries and indirectly referenced by around 5 countries. What 
impact on European pricing the change from the previously free pricing and full 
reimbursement of patented drug prices in Germany really has, after the 
implementation of the AMNOG, is quantitatively hard to assess. CONCLUSIONS: 
If Germany will follow more strictly the international price referencing in the 
future for innovative drugs based on the AMNOG process, it will lose anchor 
function in European pricing with an overall international downward effect on 
the European pricing for innovative pharmaceuticals.  
 
PRS62  
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OBJECTIVES: Atopic dermatitis (AD), also known as eczema, is a common 
chronic skin condition in childhood that has negative impact on both patients 
and their families. A survey was conducted to evaluate the disease burden, 
financial and quality of life impact of moderate to severe AD across 12 countries 
in the Asia Pacific region. In this analysis, we examine the disease burden of 
pediatric AD by country. METHODS: A cross sectional survey was conducted in 
Australia, China, Hong Kong, India, Indonesia, Korea, Malaysia, Philippines, 
Singapore, Taiwan, Thailand, and Vietnam in January, 2011. An online 
questionnaire was administered to 1028 parents with children diagnosed with 
moderate to severe AD (aged 1 t- 16 years). For the purpose of analysis, 
respondents were categorized according to country, disease severity based on 
the Nottingham Eczema Severity Score, and age group. RESULTS: In the 
population sampled, there were 27% infants (aged less than 4 years) and 73% 
children (4 - 16 years old). Approximately 60% of the respondents from all 
countries reported moderate AD. Infants and children with moderate AD 
experienced fewer flare-ups per year (median=5) compared to children with 
severe AD (median=7). There was no difference in overall flare-up duration (5 
days) between moderate and severe AD. The overall percentage of children with 
more than 6 flare-ups per year was 41%, more often seen in (≥45%) in Singapore, 
Australia, Thailand, Taiwan, and Hong Kong. Common associated conditions 
with AD were food allergies, asthma and rhinitis. CONCLUSIONS: Results of the 
survey showed that moderate to severe AD is a common condition affecting 
infants and children with an average of 5-7 flare-ups per year lasting an average 
of 5 days. The burden of AD is higher among more developed countries in the 
Asia Pacific region.  
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OBJECTIVES To heighten awareness of the changing demographics and health 
care use patterns of patients with COPD in Iowa. METHODS A retrospective 
cohort study of Iowa hospital and outpatient events associated with COPD was 
constructed from Iowa hospital discharge data. Inpatient and outpatient events 
